| abstract |
D-homo- (16-en) -11beta-aryl-4-estrènes of a new type have the general formula (I), in which X denotes an oxygen atom, the hydroxyimino group> N ~ OH or two hydrogen atoms; R1 denotes a hydrogen atom or a methyl group; R2 denotes a hydroxy group, a C1-C10 alkoxy or a C1-C10 acyloxy group; R11 denotes a fluorine, chlorine or bromine atom, while R12 and R13 together represent in this case an additional bond; or R11 denotes a C1-C4 straight or branched chain alkyl residue or a hydrogen atom, whereas R12 and R13 each denote in this case a hydrogen atom or together represent an additional bond; and R3 and R4 have the usual meaning of competitive progesterone antagonists, given in the description. The invention also relates to the pharmacologically admissible addition salts of these compounds with acids, as well as a process for the production of these new compounds, pharmaceutical compositions containing these compounds, their use for producing medicaments and the novel intermediates required. to implement this process. These new compounds have a strong affinity for the gestagen receptor and strong anti-estrogen, anti-glucocorticoid, anti-corticosteroid and anti-androgenic properties. |